Flexion Therapeutics Company Profile (NASDAQ:FLXN)

About Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics logoFlexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $823.47 million
  • Outstanding Shares: 31,905,000
Average Prices:
  • 50 Day Moving Avg: $23.38
  • 200 Day Moving Avg: $22.10
  • 52 Week Range: $15.93 - $29.41
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.97
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.38 per share
  • Price / Book: 4.05
Profitability:
  • EBIDTA: ($87,640,000.00)
  • Return on Equity: -53.94%
  • Return on Assets: -38.24%
Debt:
  • Debt-to-Equity Ratio: 0.74%
  • Current Ratio: 18.29%
  • Quick Ratio: 18.29%
Misc:
  • Average Volume: 540,272 shs.
  • Beta: 1.16
  • Short Ratio: 11.24
 

Frequently Asked Questions for Flexion Therapeutics (NASDAQ:FLXN)

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its earnings results on Tuesday, August, 8th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.11. View Flexion Therapeutics' Earnings History.

Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2017?

8 brokerages have issued 12 month price objectives for Flexion Therapeutics' stock. Their forecasts range from $0.02 to $44.00. On average, they expect Flexion Therapeutics' stock price to reach $32.56 in the next twelve months. View Analyst Ratings for Flexion Therapeutics.

What are analysts saying about Flexion Therapeutics stock?

Here are some recent quotes from research analysts about Flexion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (8/28/2017)
  • 2. Cantor Fitzgerald analysts commented, "OpEx Increases in 2017: FLXN reported 4Q16 and YE results of ($0.79) and ($2.84), below our estimates due to higher R&D and SG&A expense. Management noted on the call that R&D expense should increase given the on going repeat-dose study and manufacturing ramp with SG&A ramping through the 2H17 as launch preparation get fully underway. FLXN finished the quarter with $210M in cash which we estimate gives them funding through mid-2018. We have adjusted our estimates to reflect quarter results. PDUFA and Beyond: We view the acceptance of the NDA without the need to provide additional data as an incremental positive, removing an overhang in the minds of some investors. We see investors now turning to the prospective label with the potential for differentiation in the diabetic sub-population and a repeat- dose sNDA filing which could be on label by 2019. Additional label expansion into other joints including shoulder and hip are also possibilities though not near term." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)

Who are some of Flexion Therapeutics' key competitors?

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:

  • Patrick J. Mahaffy, Chairman of the Board
  • Michael D. Clayman M.D., President, Chief Executive Officer, Co-Founder, Director
  • Mark Levine, Senior Vice President, General Counsel, Secretary
  • Neil Bodick M.D., Ph.D., Chief Scientific Officer
  • John Magee, Vice President - Sales
  • Mark Fraga, Vice President - Marketing
  • Scott Kelley M.D., Vice President - Medical Affairs
  • Dan Thornton, Vice President - Market Access
  • Yamo Deniz M.D., Chief Medical Officer
  • Mark P. Stejbach, Director

Who owns Flexion Therapeutics stock?

Flexion Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (13.44%), Bank of New York Mellon Corp (8.55%), Capital World Investors (7.95%), State Street Corp (4.32%), Vanguard Group Inc. (3.32%) and Wasatch Advisors Inc. (3.19%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

Who sold Flexion Therapeutics stock? Who is selling Flexion Therapeutics stock?

Flexion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Russell Investments Group Ltd., Gilder Gagnon Howe & Co. LLC, Parametric Portfolio Associates LLC, TIAA CREF Investment Management LLC, Teachers Retirement System of The State of Kentucky, California State Teachers Retirement System and Peregrine Capital Management LLC. Company insiders that have sold Flexion Therapeutics stock in the last year include Frederick W Driscoll and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics.

Who bought Flexion Therapeutics stock? Who is buying Flexion Therapeutics stock?

Flexion Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, State Street Corp, Wasatch Advisors Inc., Nexthera Capital LP, Pictet Asset Management Ltd., Zweig DiMenna Associates LLC, Ardsley Advisory Partners and Schroder Investment Management Group. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy Flexion Therapeutics stock?

Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of Flexion Therapeutics stock can currently be purchased for approximately $25.81.


MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Flexion Therapeutics (NASDAQ:FLXN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $32.56 (26.14% upside)

Analysts' Ratings History for Flexion Therapeutics (NASDAQ:FLXN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Needham & Company LLCReiterated RatingBuy$36.00HighView Rating Details
9/11/2017Royal Bank Of CanadaSet Price TargetBuy$44.00LowView Rating Details
8/24/2017Northland SecuritiesInitiated CoverageOutperform -> Outperform$40.00HighView Rating Details
8/11/2017BMO Capital MarketsReiterated RatingBuyHighView Rating Details
7/12/2017Janney Montgomery ScottReiterated RatingBuy$30.00 -> $35.00HighView Rating Details
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
3/25/2017Wells Fargo & CompanyReiterated RatingOutperform$30.00MediumView Rating Details
12/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$35.00N/AView Rating Details
11/8/2016BCSLower Price Target$0.65 -> $0.02N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Flexion Therapeutics (NASDAQ:FLXN)
Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Earnings History by Quarter for Flexion Therapeutics (NASDAQ FLXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.80)($0.91)ViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.75)ViewListenView Earnings Details
3/9/2017Q4 2016($0.71)($0.79)ViewListenView Earnings Details
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
8/3/2016Q2($0.67)($0.63)ViewN/AView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
3/10/2016Q4 2015($0.58)($0.63)ViewN/AView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/23/2015Q4 2014($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.54)($0.45)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.55)($0.38)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.53)($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flexion Therapeutics (NASDAQ:FLXN)
Current Year EPS Consensus Estimate: $-3.70 EPS
Next Year EPS Consensus Estimate: $-3.24 EPS

Dividends

Dividend History for Flexion Therapeutics (NASDAQ:FLXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Flexion Therapeutics (NASDAQ:FLXN)
Insider Ownership Percentage: 15.98%
Institutional Ownership Percentage: 82.75%
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Yamo DenizInsiderBuy1,000$24.20$24,200.00View SEC Filing  
9/1/2017Yamo DenizInsiderBuy3,000$24.15$72,450.00View SEC Filing  
8/31/2017Yamo DenizInsiderBuy1,375$25.40$34,925.00View SEC Filing  
6/16/2017Mark StejbachDirectorBuy1,580$17.02$26,891.60View SEC Filing  
6/5/2017Michael D ClaymanInsiderBuy5,000$17.23$86,150.00View SEC Filing  
4/17/2017Neil BodickInsiderSell5,000$28.23$141,150.00View SEC Filing  
3/23/2017Frederick W DriscollCFOSell3,000$23.00$69,000.00View SEC Filing  
3/17/2017Neil BodickInsiderSell5,000$20.41$102,050.00View SEC Filing  
2/24/2017Neil BodickInsiderSell5,000$19.15$95,750.00View SEC Filing  
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.00View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.00View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.00View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.47View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.70View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.40View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.00View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.84View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.52View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.00View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.00View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.00View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.00View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.00View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.00View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.00View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.00View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.00View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.00View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.00View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.00View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.00View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Flexion Therapeutics (NASDAQ:FLXN)
Latest Headlines for Flexion Therapeutics (NASDAQ:FLXN)
Source:
DateHeadline
nasdaq.com logoImplied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options - Nasdaq
www.nasdaq.com - September 19 at 11:46 PM
finance.yahoo.com logoImplied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options
finance.yahoo.com - September 19 at 6:43 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Given "Buy" Rating at Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
americanbankingnews.com logoInsider Buying: Flexion Therapeutics, Inc. (FLXN) Insider Purchases 1,375 Shares of Stock
www.americanbankingnews.com - September 15 at 8:30 PM
americanbankingnews.com logoInsider Buying: Flexion Therapeutics, Inc. (FLXN) Insider Purchases 1,000 Shares of Stock
www.americanbankingnews.com - September 15 at 8:30 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Insider Buys $72,450.00 in Stock
www.americanbankingnews.com - September 15 at 8:28 PM
americanbankingnews.com logo-$0.95 Earnings Per Share Expected for Flexion Therapeutics, Inc. (FLXN) This Quarter
www.americanbankingnews.com - September 15 at 6:22 PM
americanbankingnews.com logoRoyal Bank Of Canada Analysts Give Flexion Therapeutics, Inc. (FLXN) a $44.00 Price Target
www.americanbankingnews.com - September 11 at 9:32 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 9 at 2:50 PM
streetinsider.com logoFlexion Therapeutics (FLXN) to Present Data on Zilretta at PAINWeek - StreetInsider.com
www.streetinsider.com - September 7 at 11:55 PM
finance.yahoo.com logoFlexion Therapeutics to Present Data on Zilretta™ (FX006) at PAINWeek 2017
finance.yahoo.com - September 7 at 6:53 PM
americanbankingnews.com logoValuEngine Upgrades Flexion Therapeutics, Inc. (FLXN) to Hold
www.americanbankingnews.com - September 3 at 12:16 PM
globenewswire.com logoFlexion Therapeutics to Present at the 2017 Wells Fargo Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 30 at 8:00 PM
finance.yahoo.com logoFlexion Therapeutics to Present at the 2017 Wells Fargo Healthcare Conference
finance.yahoo.com - August 30 at 8:00 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - August 29 at 12:28 AM
seekingalpha.com logoFlexion Therapeutics: Updates To Thesis - Seeking Alpha
seekingalpha.com - August 28 at 3:52 AM
seekingalpha.com logoFlexion Therapeutics Inc.: Teeing up to disrupt the osteoarthritis market
seekingalpha.com - August 24 at 8:04 PM
americanbankingnews.com logoNorthland Securities Begins Coverage on Flexion Therapeutics, Inc. (FLXN)
www.americanbankingnews.com - August 24 at 1:38 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 15 at 9:08 PM
americanbankingnews.com logoFlexion Therapeutics' (NASDAQ:FLXN) Buy Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - August 13 at 8:32 PM
americanbankingnews.com logoFlexion Therapeutics' (NASDAQ:FLXN) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - August 10 at 3:20 PM
americanbankingnews.com logo Analysts Expect Flexion Therapeutics, Inc. (NASDAQ:FLXN) Will Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - August 9 at 8:24 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (NASDAQ:FLXN) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 9 at 7:48 PM
nasdaq.com logoFlexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights - Nasdaq
www.nasdaq.com - August 9 at 6:53 PM
finance.yahoo.com logoEdited Transcript of FLXN earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 6:53 PM
seekingalpha.com logoFlexion Therapeutics' (FLXN) CEO Mike Clayman on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 4:29 AM
finance.yahoo.com logoFlexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights
finance.yahoo.com - August 8 at 6:26 PM
finance.yahoo.com logoFlexion Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 6:26 PM
fool.com logo3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic - Motley Fool
www.fool.com - August 3 at 12:38 AM
finance.yahoo.com logo3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic
finance.yahoo.com - August 2 at 7:36 PM
finance.yahoo.com logoFlexion Therapeutics to Report Second-Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - August 1 at 7:21 PM
prnewswire.com logoHow These Generic Drugs Stocks are Performing? -- Akari Therapeutics, Flexion ...
www.prnewswire.com - July 31 at 6:24 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 8:47 PM
finance.yahoo.com logo4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings
finance.yahoo.com - July 17 at 10:37 AM
americanbankingnews.com logoFlexion Therapeutics, Inc. (NASDAQ:FLXN) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 14 at 12:05 AM
thestreet.com logoBiotech Movers: Ocular, Alder, Flexion - TheStreet.com
www.thestreet.com - July 12 at 7:23 PM
americanbankingnews.com logoJanney Montgomery Scott Reaffirms Buy Rating for Flexion Therapeutics, Inc. (FLXN)
www.americanbankingnews.com - July 12 at 9:26 AM
streetinsider.com logoFlexion Therapeutics (FLXN) FVE Raised to $35 at Janney ... - StreetInsider.com
www.streetinsider.com - July 11 at 7:51 PM
globenewswire.com logoFlexion Therapeutics to Hold Investor & Analyst Day Today - GlobeNewswire (press release)
globenewswire.com - July 10 at 6:39 PM
finance.yahoo.com logoFlexion Therapeutics to Hold Investor & Analyst Day Today
finance.yahoo.com - July 10 at 6:39 PM
streetinsider.com logoFlexion Therapeutics (FLXN): Buy Into Monday's Analyst Day, October PDUFA - RBC - StreetInsider.com
www.streetinsider.com - July 9 at 1:49 AM
seekingalpha.com logoFlexion Therapeutics: Flexin' Its Price Target - Seeking Alpha
seekingalpha.com - July 9 at 1:49 AM
americanbankingnews.com logoRoyal Bank Of Canada Reaffirms Buy Rating for Flexion Therapeutics, Inc. (FLXN)
www.americanbankingnews.com - July 7 at 9:28 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 6 at 12:26 AM
globenewswire.com logoFlexion Therapeutics to Hold Investor and Analyst Day on July 10, 2017 - GlobeNewswire (press release)
globenewswire.com - July 5 at 6:40 AM
finance.yahoo.com logoFlexion Therapeutics to Hold Investor and Analyst Day on July 10, 2017
finance.yahoo.com - July 3 at 6:26 PM
seekingalpha.com logoFlexion Looks Good With Upcoming FDA Catalyst - Seeking Alpha
seekingalpha.com - June 29 at 8:15 PM
seekingalpha.com logoThe Investment Case For Flexion Therapeutics - Seeking Alpha
seekingalpha.com - June 29 at 4:23 AM
finance.yahoo.com logoFlexion Therapeutics Announces Appointment of Mark Levine as General Counsel
finance.yahoo.com - June 28 at 6:17 PM
americanbankingnews.com logoBMO Capital Markets Reiterates Buy Rating for Flexion Therapeutics, Inc. (FLXN)
www.americanbankingnews.com - June 27 at 9:52 AM

Social

Chart

Flexion Therapeutics (FLXN) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff